TY - JOUR
T1 - The role of incretins and incretin-based drugs in autoimmune diseases
AU - Radbakhsh, Shabnam
AU - Atkin, Stephen L.
AU - Simental-Mendia, Luis E.
AU - Sahebkar, Amirhossein
PY - 2021/9
Y1 - 2021/9
N2 - Incretin hormones, including glucagon-like peptide (GLP)-1, GLP-2 and glucose-dependent insulinotropic polypeptide (GIP), are gastrointestinal peptides secreted from enteroendocrine cells. These hormones play significant roles in many physiological processes via binding to G-protein coupled receptors (GPCRs) on different organs and tissues; one of them is the immunomodulatory effect on the immune system and its molecular components such as cytokines and chemokines. Anti-inflammatory effects of incretins and dependent molecules involving long-acting analogs and DPP4 inhibitors through regulation of T and B cell activation may attenuate autoimmune diseases caused by immune system disorders in mistakenly recognizing self as the foreign agent. In this review, we investigate incretin effects on the immune system response and the potential benefits of incretin-based therapy for treating autoimmune diseases.
AB - Incretin hormones, including glucagon-like peptide (GLP)-1, GLP-2 and glucose-dependent insulinotropic polypeptide (GIP), are gastrointestinal peptides secreted from enteroendocrine cells. These hormones play significant roles in many physiological processes via binding to G-protein coupled receptors (GPCRs) on different organs and tissues; one of them is the immunomodulatory effect on the immune system and its molecular components such as cytokines and chemokines. Anti-inflammatory effects of incretins and dependent molecules involving long-acting analogs and DPP4 inhibitors through regulation of T and B cell activation may attenuate autoimmune diseases caused by immune system disorders in mistakenly recognizing self as the foreign agent. In this review, we investigate incretin effects on the immune system response and the potential benefits of incretin-based therapy for treating autoimmune diseases.
KW - Autoimmune diseases
KW - DPP4 inhibitor
KW - GIP
KW - GLP1
KW - Incretin receptor agonist
KW - Incretin-based therapy
UR - http://www.scopus.com/inward/record.url?scp=85107962618&partnerID=8YFLogxK
U2 - 10.1016/j.intimp.2021.107845
DO - 10.1016/j.intimp.2021.107845
M3 - Review article
C2 - 34126341
AN - SCOPUS:85107962618
SN - 1567-5769
VL - 98
JO - International Immunopharmacology
JF - International Immunopharmacology
M1 - 107845
ER -